Therapeutic Drug Monitoring of the Biosimilar (AMJEVITA™, Adalimumab-atto) Using Labcorp Adalimumab Assay for Drug Level and Anti-Drug Antibodies

被引：0
|
作者：
Chun, Kelly Y. [1 ]
Bastidas, Monique [1 ]
Yeo, Lythou [1 ]
Magpantay, Susie [1 ]
Scott, Judah [1 ]
Zikry, Michael [1 ]
Galdamez, Wayne [1 ]
机构：
[1] LabCorp, Calabasas, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 12S期
关键词：
D O I：
10.14309/01.ajg.0000995804.85093.96
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S17
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [1] Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
    Bastidas, Monique
    Yeo, Lythou
    Magpantay, Susie
    Scott, Judah
    Zikry, Mike
    Galdamez, Wayne
    Yang, Jane
    Chun, Kelly
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 937 - 938
  • [2] Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS™, Infliximab-abda) Using LabCorp Infliximab Assays for Drug Level and Anti-drug Antibodies
    Kelly, Chun
    Zonia, Garcia Gonzalez
    Jane, Yang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S25 - S25
  • [3] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [4] PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
    Perinbasekar, Rajiv A.
    Brown, Sara A.
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond K.
    GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
  • [5] DETECTING ADALIMUMAB SERUM LEVEL AND ANTI-DRUG ANTIBODIES - FUTURE TOOL IN MONITORING SPONDYLOARTHRITIS PATIENTS?
    Deaconu, C.
    Opris, D.
    Mazilu, D.
    Borangiu, A.
    Groseanu, L.
    Negru, M.
    Constantinescu, C.
    Saulescu, I.
    Bojinca, V.
    Vlad, V.
    Balanescu, A.
    Predeteanu, D.
    Ionescu, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : A75 - A75
  • [6] Biologic Therapeutic Drug Monitoring (TDM) of Infliximab and Adalimumab: Serial Monitoring and Distribution of Drug and Anti-Drug Antibodies in 125,950 Patient Samples
    Yang, Jane
    Chun, Kelly
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S946 - S946
  • [7] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
  • [8] Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays
    Vroemen, Wim H. M.
    Agata, Shakira S.
    van Beers, Joyce J. B. C.
    Damoiseaux, Jan G. M. C.
    ANTIBODIES, 2024, 13 (03)
  • [9] Factors that may influence the development of anti-drug antibodies to adalimumab
    Reinisch, W.
    Rauter, I.
    Chen, L.
    Gessner, M.
    Fanjiang, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S429 - S430
  • [10] Adalimumab/infliximabDevelopment of anti-drug antibodies: 7 case reports
    Reactions Weekly, 2018, 1701 (1) : 15 - 15
12345